Cargando…
Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer
SIMPLE SUMMARY: Over the last two decades, our improved understanding of the pathobiology of androgen-addicted prostate cancer (PCa), and documented therapeutic advances/breakthroughs have not translated into any substantial or sustained curative benefit for patients treated with traditional ADT or...
Autores principales: | Bamodu, Oluwaseun Adebayo, Tzou, Kai-Yi, Lin, Chia-Da, Hu, Su-Wei, Wang, Yuan-Hung, Wu, Wen-Ling, Chen, Kuan-Chou, Wu, Chia-Chang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303483/ https://www.ncbi.nlm.nih.gov/pubmed/34298692 http://dx.doi.org/10.3390/cancers13143478 |
Ejemplares similares
-
THU574 Hsd17b1 Partially Compensates For The Lack Of Hsd17b3 In Testicular Testosterone Production In Fetal Mice, But Not In Adults
por: Poutanen, Matti, et al.
Publicado: (2023) -
New Insights into Testosterone Biosynthesis: Novel Observations from HSD17B3 Deficient Mice
por: Lawrence, Ben M., et al.
Publicado: (2022) -
HSD17B13: A Potential Therapeutic Target for NAFLD
por: Zhang, Hai-bo, et al.
Publicado: (2022) -
SUN-213 Hsd17b3 Knockout Mice Serve As A Model To Define Mechanisms Behind The Altered Endocrine Phenotype Of Patients With Hsd17b3 Mutations
por: Poutanen, Matti, et al.
Publicado: (2019) -
Genetic Variation in the HSD17B1 Gene and Risk of Prostate Cancer
por: Kraft, Peter, et al.
Publicado: (2005)